Flavonoids (Diosmin) and Chronic Venous Insufficiency — What Does the Meta-Analysis Show?

Chronic venous insufficiency (CVI) is one of the most common — and most routinely dismissed — circulatory conditions in the adult population. At its root is dysfunction of the valves inside the veins of the legs: valves that normally push blood back toward the heart against gravity gradually lose their seal. Blood starts pooling in the leg veins, pressure inside the vessels rises, and this produces a characteristic set of symptoms: a feeling of heaviness and tightness in the calves, swelling around the ankles that shows up especially in the evening, nighttime cramps, and, in more advanced cases, visible varicose veins and skin discoloration.

The problem worsens with age, but it also affects a significant share of younger and middle-aged people — especially those whose jobs require standing for hours at a time (hairdressers, nurses, retail staff) or sitting for hours (office work, long travel), as well as pregnant women, whose hormonal changes and rising abdominal pressure add extra strain on the leg venous system. Obesity and family history further raise the risk. The scale of the problem is large enough that in many European countries, a significant share of the adult population reports some degree of venous insufficiency symptoms — making this a far more common topic than the relative silence around it would suggest.

This article focuses on one specific group of supplements — flavonoids, and more precisely a micronized purified flavonoid fraction (MPFF) based mainly on diosmin — and on what a large, well-designed meta-analysis of randomized trials says about their effectiveness. This is a separate topic from flavonoids used for hemorrhoids, even though both uses rest on a similar, general mechanism of flavonoid action on venous vessels — we cover that other use and that other study in a separate article.

MPFF (micronized purified flavonoid fraction) is a standardized blend of citrus flavonoids, roughly 90% diosmin with a small share of hesperidin and related flavonoids. Micronization — breaking the molecules down to very small particle sizes — is meant to increase the bioavailability of the active substance compared to the non-micronized forms of diosmin used previously. Preparations of this type have been registered and used for decades in many European countries to treat the symptoms of chronic venous insufficiency.

The proposed mechanism of action — treated in the literature as plausible, though not every element has been conclusively confirmed at the molecular level in humans — involves several related pathways: improving venous wall tone, which limits stretching and blood pooling in the veins; reducing capillary permeability, which limits fluid leaking into tissue and, with it, swelling; and an anti-inflammatory effect that limits leukocyte adhesion and activation in the venous microcirculation, considered an important part of the pathomechanism of the chronic inflammation that accompanies venous insufficiency.

The strongest available evidence on the effectiveness of MPFF in chronic venous insufficiency is a systematic review and meta-analysis published in International Angiology in 2018, covering exclusively randomized, double-blind, placebo-controlled trials — the strongest type of methodological evidence available for this kind of intervention.

It's worth noting the spread in effect size across the symptoms measured. Leg heaviness improved the most strongly and consistently of all the parameters assessed — an SMD of -0.80 counts as a large effect by the classic conventions for interpreting this metric. Swelling as measured by ankle circumference (SMD -0.59) and cramps (SMD -0.46) fell in the moderate range. Quality of life improved the least of the four parameters (SMD -0.21) — which is actually typical for subjective, multidimensional quality-of-life questionnaires, which are harder to move than a single, concrete symptom.

A low NNT also matters practically for the patient themselves: you don't have to take the statistics on faith to notice the effect, because at such a low NNT, a substantial share of people using the preparation genuinely feel a difference, rather than only a small, group-averaged result that an individual patient wouldn't subjectively register. This sets it apart from many other supplements, where the effect is statistically significant but small enough that it's often hard for a single person to notice in daily life.

It's also worth noting that the meta-analysis itself doesn't describe the long-term safety profile in detail, nor does it directly compare MPFF with other symptomatic treatment methods (such as compression therapy) — it provides evidence of an advantage over placebo, not a ranking of all available therapeutic options against each other.

It's rare to find a supplement topic backed by such a consistent body of evidence: seven randomized trials, close to 1,700 patients, minimal heterogeneity in results, and an effect on a key symptom — leg heaviness — at a level rarely seen in symptomatic medicine (NNT=2.0). That's reason enough to treat MPFF as a genuine, well-documented supportive option for people with mild-to-moderate chronic venous insufficiency, alongside — not instead of — well-known non-pharmacological measures and regular phlebology evaluation where indicated.